Endocrine Abstracts

Osteoporosis is a progressive disease characterized by excessive bone loss which is often accompanied by augments in marrow adiposity as a result of estrogen deficiency, metabolic abnormalities or medications. Nuclear receptor estrogen-related receptor alpha (ESRRA) has a demonstrated role in energy homeostasis and fat metabolism. To determine if ESRRA is a potential therapeutic target for regulating fat-bone balance, we generated an adipocyte-specific ESRRA knockout mice (ESR...

Background: Lu-NETs are a heterogeneous family of neoplasms ranging from quite indolent lesions with extremely aggressive tumors with very poor prognosis. These neuroendocrine entities are further summarized into two groups according to their biological aggressiveness: Well-differentiated: carcinoids typical (G1) and atypical (G2).Poorly-differentiate: SCLC (Combined) and LCNEC (Combined) (G3). Alarm signal on the aggressive evolution of the SCLCCase rep...

Background: There is no universally accepted first-line (1L) therapy for higher grade, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The Phase 3 NETTER-2 study (NCT03972488) evaluated [177 Lu]Lu-DOTA-TATE (hereafter177 Lu-DOTATATE) as 1L treatment in patients with grade (G)2 and G3 advanced GEP-NETs. This is the first trial to assess 1L radioligand therapy (RLT) in any solid tumor.Methods: Eligible pat...

Background: GEP-NETS and PPGLs in pediatric patients are rare; however, recognition of these diseases has increased recently. 10–20% of pediatric patients with GEP-NETs and up to 47% of pediatric patients with PPGLs present with metastatic disease at diagnosis. The disease is often unresectable with poor prognosis, and very few non-surgical therapies are approved for these patients. Due to paucity of data surrounding treatments for pediatric patients with advanced GEP-NET...

Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme in the synthesis and repair of DNA, making RNR-targeted therapy a rationale therapeutic strategy for radiosensitization. ETCTN 10388 (NCT04234568) evaluated safety and efficacy of the combination of lutetium 177 DOTATATE, a beta-emitting radionuclide in combination with triapine, a ribonucleotide reductase (RNR) inhibitor. <p class="abstext"...

Introduction: Lutetium-177-DOTATATE (Lu177) is approved in patients with well-differentiated (G1 and G2) neuroendocrine tumors (NETs) positive to somatostatin receptors, progressive and unresectable or metastatic. Lu177 has been shown to increase progression-free survival and the quality of life of these patients.Material and Methods: Retrospective descriptive study of a series of 15 cases with NETs treated with Lu177. Demographic data, tumor characteris...

Introduction: Neuroendocrine tumors (NETs) are rare and their clinical behavior and prognosis correlates with mitotic rate and Ki-67 index. Most patients with advanced NET have liver metastases unresectable and somatostatin analogues are the initial therapy of choice but when disease progresses despite treatment and there are positive somatostatin receptors, peptide receptor radioligand therapy (PRRT), using lutetium-177, is a therapeutic option.Clinical...

Malignant insulinoma is an extremely uncommon tumor (5–10% of insulinomas). It is accompanied by severe hypoglycemia and a short life expectancy (survival at 10 years <10%). Its clinical management is complex and constitutes a real therapeutic challenge. So far, the experience of radionuclide treatment in these tumors is scarce. We report the case of a 51-year-old woman diagnosed with pancreatic neuroendocrine tumor (pNET) in January 2013. Pre-surgical imaging study b...

Background: 177Lu-DOTATATE is increasingly used in patients with advanced neuroendocrine tumour (NET). However, few circulating biomarkers are available to predict progression-free survival (PFS) of patients received 177Lu-DOTATATE.Materials and methods: Clinicopathological data and data of baseline circulating biomarkers including neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lymphocyte-monocyte ratio (LMR), e...

Objective: Decline in the number of D2 receptor (D2R) is considered as the reason of resistance to dopamine agonists (DA). PP4R2 gene was observed up-regulated in prolactinoma patients according to our previous genechip study. In this study, we demonstrated that PP4C was crucial for D2R expression and PRL secretion in rat pituitary MMQ cells.Methods: In this study, we used rat pituitary MMQ cells which could secrete abundant prolactin and express functio...